Multiplex analysis of the immune environment before and after neoadjuvant durvalumab as a prognostic factor in resectable NSCL
IFCT-1601 IONESCO à l'ASCO 2024
- Details
Select your language
Select your language
Multiplex analysis of the immune environment before and after neoadjuvant durvalumab as a prognostic factor in resectable NSCL